1.46
-0.03 (-2.01%)
| Previous Close | 1.49 |
| Open | 1.50 |
| Volume | 511,768 |
| Avg. Volume (3M) | 1,069,945 |
| Market Cap | 116,226,376 |
| Price / Earnings (TTM) | 29.20 |
| Price / Earnings (Forward) | 29.41 |
| Price / Sales | 2.18 |
| Price / Book | 2.59 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Profit Margin | 6.54% |
| Operating Margin (TTM) | -40.99% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 169.80% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | 8.67 M |
| Levered Free Cash Flow (TTM) | -3.29 M |
| Return on Assets (TTM) | 3.53% |
| Return on Equity (TTM) | 10.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.39% |
| % Held by Institutions | 10.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stratos Wealth Partners, Ltd. | 30 Jun 2025 | 350,000 |
| Omers Administration Corp | 31 Mar 2025 | 179,300 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results |
| 07 Aug 2025 | Announcement | Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 |
| 21 Jul 2025 | Announcement | Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer |
| 30 Jun 2025 | Announcement | Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |